Related Experiment Video
Updated: Dec 30, 2025
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
Cell free DNA as a diagnostic and prognostic marker for cardiovascular diseases
Iuliia A Polina1, Daria V Ilatovskaya1, Kristine Y DeLeon-Pennell2
1Department of Medicine, Division of Nephrology, and Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC 29425, USA.
Insights
Cell-free DNA (cfDNA) is a vital biomarker for cardiovascular diseases (CVD). This review explores cfDNA release mechanisms and its role in predicting outcomes for myocardial infarction, heart failure, and hypertension.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Medicine
Background:
- Cell-free DNA (cfDNA) is released from dying cells during normal physiological processes.
- cfDNA is increasingly recognized as a significant biomarker in cardiovascular disease (CVD).
- Research is actively investigating the mechanisms of cfDNA release and its prognostic value.
Purpose of the Study:
- To review the pathways of cfDNA release in major cardiovascular conditions.
- To discuss the utility of cfDNA monitoring for assessing disease progression.
- To highlight the potential of cfDNA in predicting future cardiovascular complications.
Main Methods:
- Literature review of studies on cfDNA release mechanisms.
- Analysis of cfDNA's role in myocardial infarction, heart failure, and hypertension.
- Synthesis of current knowledge on cfDNA as a prognostic marker.
Main Results:
- Identified key pathways responsible for cfDNA release in cardiovascular disease.
- Demonstrated the potential of cfDNA levels to reflect disease status.
- Highlighted cfDNA's predictive capacity for adverse cardiovascular events.
Conclusions:
- cfDNA represents a promising biomarker for diagnosing and monitoring cardiovascular diseases.
- Understanding cfDNA release mechanisms can lead to improved patient management.
- Monitoring cfDNA may offer valuable insights into predicting cardiovascular complications.
Abstract:
Release of cell free DNA (cfDNA) from damaged or dead cells routinely occurs in normal physiology. Recently, cfDNA has emerged as an essential biomarker in cardiovascular disease (CVD) of potential prognostic and diagnostic significance. Within the last decade, significant research efforts have been devoted to uncovering the mechanisms mediating cfDNA release and its outcome-predicting ability. The current review focuses on the pathways for cfDNA release in myocardial infarction, heart failure and hypertension, and discusses implementation of cfDNA monitoring to assess the overall development of these disease states and predict future complications.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:30Coronary Artery Disease I: Introduction